66869-71-4

Usage

Uses

Used in Organic Synthesis:
Ethyl 3-(4-Pyridyl)propiolate is used as a key intermediate in the synthesis of various organic compounds, facilitating the creation of a wide range of chemical products due to its reactivity and functional group compatibility.
Used in Pharmaceutical Research:
In the pharmaceutical industry, Ethyl 3-(4-Pyridyl)propiolate serves as a valuable precursor for the development of new drugs, contributing to the advancement of medicinal chemistry through its unique structural properties and potential for molecular modification.
Used in Agrochemical Development:
Ethyl 3-(4-Pyridyl)propiolate is utilized as a building block in the formulation of agrochemicals, playing a role in the creation of pesticides, herbicides, and other agricultural products to enhance crop protection and yield.
Used in Specialty Chemicals:
Ethyl 3-(4-Pyridyl)propiolate finds application in the development of specialty chemicals, where its unique properties can be tailored for specific industrial needs, such as in the production of dyes, fragrances, or other high-value chemical products.

Upstream product

• 26377-17-3 ethyl 3-oxo-3-(4-pyridyl)propanoate 
• 15854-87-2 4-iodopyridine 
• 623-47-2 propynoic acid ethyl ester 
• 55-22-1 pyridine-4-carboxylic acid 
• 14254-57-0 4-(chlorocarbonyl)pyridine 

Downstream Products

• 1378868-77-9 ethyl 6-(N-(4-bromo-3-fluorobenzyl)methylsulfonamido)-5-cyclopropyl-2-(pyridin-4-yl)pyrazolo[1,5-a]pyridine-3-carboxylate 
• 1378868-35-9 (4-((N-(5-cyclopropyl-3-(methylcarbamoyl)-2-(pyridin-4-yl)pyrazolo[1,5-a]pyridin-6-yl)methylsulfonamido)methyl)-2-fluorophenyl)boronic acid 
• 1378868-83-7 5-cyclopropyl-6-(N-(3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)methylsulfonamido)-N-methyl-2-(pyridin-4-yl)pyrazolo[1,5-a]pyridine-3-carboxamide 
• 1378868-81-5 6-(N-(4-bromo-3-fluorobenzyl)methylsulfonamido)-5-cyclopropyl-N-methyl-2-(pyridin-4-yl)pyrazolo[1,5-a]pyridine-3-carboxamide 
• 1378868-79-1 6-(N-(4-bromo-3-fluorobenzyl)methylsulfonamido)-5-cyclopropyl-2-(pyridin-4-yl)pyrazolo[1,5-a]pyridine-3-carboxylic acid 

Relevant academic research and scientific papers

Consecutive Three-Component Coupling-Addition Synthesis of β-Amino Enoates and 3-Hydroxypyrazoles via Ethyl 3-Arylpropiolates

Two consecutive three-component syntheses furnishing β-amino enoates or 3-hydroxypyrazoles based upon the Sonogashira alkynylation of aryl iodides and ethyl propiolate were established in mostly excellent yields. The ethyl 3-arylpropiolate intermediates are Michael systems which are suited for concatenation with conjugate addition or cyclocondensation giving access to libraries of 21 different β-amino enoates and 17 different 3-hydroxypyrazoles. The rotational barrier of β-pyrrolidino enoates was assessed by studying the coalescence of pyrrolidinyl protons in VT-NMR spectra of electronically different substituted derivatives showing that the electronic substituent effect on the aryl group does not affect the height of the rotational barrier. This indicates that the substituents are essentially oriented orthogonally to the plane of the β-pyrrolidino enoates.

3-Phenothiazinyl propiolates – Fluorescent electrophores by Sonogashira coupling of ethyl propiolate

Fluorescent ethyl 3-phenothiazinyl propiolates with reversible Nernstian oxidation potentials were efficiently synthesized by an improved Sonogashira coupling of aryl iodides and ethyl propiolate. The versatility of this modified alkynylation was illustrated by 13 ethyl 3-arylpropiolates in mostly excellent yields with a broad substrate scope. In addition to reversible one-electron oxidations, the title compounds reveal large Stokes shifts, high fluorescence quantum yields, and solvatochromic emission. The photophysical characteristics were corroborated and rationalized by DFT and TD-DFT calculations.

Substituted indoles and their use as integrin antagonists

The present invention relates to novel substituted indole compounds that are antagonists of alpha V (αv) integrins, for example αvβ3 and αvβ5 integrins, their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. The compounds may be used in the treatment of pathological conditions mediated by αvβ3 and αvβ5 integrins, including such conditions as tumor growth, metastasis, restenosis, osteoporosis, inflammation, macular degeneration, diabetic retinopathy, and rheumatoid arthritis. The compounds have the general formula: where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, D, X, W, a, m, n, i, j, k and v are defined herein.